The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer - PubMed
4 days ago
- #ZNF737
- #Immune Evasion
- #Bladder Cancer
- The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.
- ZNF737, a transcription factor, is identified as a key driver of immune evasion in bladder cancer.
- ZNF737 directly represses the chemokine CXCL10, impairing CD8+ T cell recruitment and promoting cancer cell migration.
- Depletion of ZNF737 in humanized mice transforms the tumor microenvironment from 'immune-desert' to 'inflamed,' enhancing anti-PD-1 therapy response.
- High ZNF737 expression predicts primary resistance to immune checkpoint blockade (ICB) in clinical cohorts.
- ZNF737 serves as a complementary biomarker to PD-L1 for predicting ICB resistance and is a potential therapeutic target.